Dynavax Technologies Corporation (NASDAQ: DVAX), a
biopharmaceutical company focused on developing and commercializing
novel vaccines, and Albertsons Companies, one of the largest food
and drug retailers in the United States, have partnered to provide
HEPLISAV-B at Albertsons Companies’ more than 1,700 pharmacies
nationwide, with a special focus on people living with diabetes.
Through this partnership, patients will have access to HEPLISAV-B,
the only FDA-approved two-dose hepatitis B vaccine for adults that
is completed in one month. HEPLISAV-B is indicated for prevention
of infection caused by all known subtypes of hepatitis B virus in
adults age 18 years and older.
“Immunizations are an important part of preventative care and
are crucial to preventing the spread of serious illness, like
hepatitis B,” said Brian Hille, Vice President, Patient, Specialty
and Wellness Services, Albertsons Companies. “Because diabetic
patients are two times more likely to become infected with the
hepatitis B virus and up to four times as likely to get HBV-related
liver cancer, it makes sense to increase access to the HEPLISAV-B
vaccine for these patients at our pharmacies, which are low
barrier, easy access health and wellness centers in our
communities.”
Hepatitis B is a liver infection caused by the hepatitis B virus
(HBV). It is estimated that 15 to 25 percent of patients with
chronic hepatitis B develop chronic liver disease, including
cirrhosis, liver failure, or liver cancer.i People living with
diabetes are at increased risk for hepatitis B since the hepatitis
B virus can be spread through everyday disease management
activities such as sharing blood glucose meters, fingerstick
devices or other diabetes-care equipment including syringes or
insulin pens.ii The CDC recommends HBV vaccination for all adults
with diabetes who are younger than 60 years old.iii
“We are committed to the prevention of hepatitis B by ensuring
access to vaccines in all sites of care,” said Ryan Spencer,
Co-President for Dynavax. "Community pharmacists play a major
role in immunizing patients in their neighborhoods, and we are
pleased that Albertsons Companies’ pharmacists will be able to help
educate patients at risk for hepatitis B and conveniently provide
vaccination with HEPLISAV-B.”
No appointment is necessary to receive the HEPLISAV-B
vaccination at Albertsons Companies’ pharmacies during normal
business hours. Hepatitis B vaccine and other vaccines, as
permitted per state law, can be administered on a “walk-in” basis
and are offered at more than 1,700 Albertsons Companies’ pharmacy
locations, including those in Albertsons, Safeway, Vons,
Jewel-Osco, Shaw's, Acme, Tom Thumb, Randalls, Pavilions, Star
Market, Haggen, and Carrs stores. Private insurers, Medicare and
Medicaid are required to cover preventative HBV testing and
vaccines usually without a deductible or co-pay. Payer coverage for
HEPLISAV-B has been established for 100% of Medicare lives, more
than 95% of Commercial lives, and 90% of Medicaid fee-for-service
lives.
Please see Important Safety Information below.
For more information about HEPLISAV-B,
visit http://heplisavb.com/.
About Hepatitis B Hepatitis B is a viral
disease of the liver that can become chronic and lead to cirrhosis,
liver cancer and death. The hepatitis B virus is 50 to 100 times
more infectious than HIV,iv and transmission is on the rise. There
is no cure for hepatitis B, but effective vaccination can prevent
the disease.
In adults, hepatitis B is spread through contact with infected
blood and through unprotected sex with an infected person. The CDC
recommends vaccination for those at high risk for infection due to
their jobs, lifestyle, living situations and travel to certain
areas.v Because people with diabetes are particularly vulnerable to
infection, the CDC recommends vaccination for adults age 19 to 59
with diabetes as soon as possible after their diagnosis, and for
people age 60 and older with diabetes at their physician's
discretion.vi Approximately 20 million U.S. adults have diabetes,
and 1.5 million new cases of diabetes are diagnosed each
year.vii
About HEPLISAV-B HEPLISAV-B is an adult
hepatitis B vaccine that combines hepatitis B surface antigen
with Dynavax's proprietary Toll-like Receptor (TLR) 9
agonist to enhance the immune response. Dynavax has
worldwide commercial rights to HEPLISAV-B.
Indication and Use HEPLISAV-B is
indicated for prevention of infection caused by all known subtypes
of hepatitis B virus in adults age 18 years and older.
Important Safety Information (ISI) Do not
administer HEPLISAV-B to individuals with a history of severe
allergic reaction (e.g., anaphylaxis) after a previous dose of any
hepatitis B vaccine or to any component of HEPLISAV-B, including
yeast.
Appropriate medical treatment and supervision must be available
to manage possible anaphylactic reactions following administration
of HEPLISAV-B.
Immunocompromised persons, including individuals receiving
immunosuppressant therapy, may have a diminished immune response to
HEPLISAV-B.
Hepatitis B has a long incubation period. HEPLISAV-B may not
prevent hepatitis B infection in individuals who have an
unrecognized hepatitis B infection at the time of vaccine
administration.The most common patient reported adverse reactions
reported within 7 days of vaccination were injection site pain (23%
to 39%), fatigue (11% to 17%) and headache (8% to 17%).
For full Prescribing Information for
HEPLISAV-B, click here.
About Dynavax Dynavax is a commercial
stage biopharmaceutical company developing and commercializing
novel vaccines. The Company launched its first commercial product,
HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], in
February 2018, following U.S. FDA approval for prevention of
infection caused by all known subtypes of hepatitis B virus in
adults age 18 years and older. For more information,
visit www.dynavax.com and follow the company
on LinkedIn.
About Albertsons Companies Locally great and
nationally strong, Albertsons Companies is one of the largest food
and drug retailers in the United States. We operate stores across
34 states and the District of Columbia under 20 well-known banners
including Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, Acme, Tom
Thumb, Randalls, United Supermarkets, Pavilions, Star Market,
Haggen and Carrs, as well as meal kit company Plated based in New
York City. Albertsons Companies is committed to helping people
across the country live better lives by making a meaningful
difference, neighborhood by neighborhood. In 2018 alone, along with
the Albertsons Companies Foundation, the company gave $262 million
in food and financial support. These efforts helped millions of
people in the areas of hunger relief, education, cancer research
and treatment, programs for people with disabilities and veterans’
outreach.
Forward-Looking Statements This press
release contains forward-looking statements, including statements
regarding the commercialization of HEPLISAV-B. These statements are
subject to a number of risks and uncertainties that could cause
actual results to differ materially, including whether the company
will be able to continue building the commercial infrastructure
required to successfully launch HEPLISAV-B; and whether payers will
provide timely reimbursement for HEPLISAV-B. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business
of Dynavax in general, see risks detailed in the "Risk
Factors" section of our most recent current periodic report filed
with the SEC. These statements represent our estimates and
assumptions only as of the date of this press release. We do not
undertake any obligation to update publicly any such
forward-looking statements, even if new information becomes
available. Information on Dynavax's website
at www.dynavax.com is not incorporated by reference in
our current periodic reports with the SEC.
Media Contact Elizabeth FatonePh. (310)
963-5221ElizabethFatone@SamBrown.com
Investor ContactNicole ArndtPh. (510)
665-7264narndt@dynavax.com
US-19-02-0035
i CDC. https://www.cdc.gov/hepatitis/abc/index.htm
ii CDC.
https://www.cdc.gov/diabetes/pubs/pdf/hepb_vaccination.pdf
iii CDC.
https://www.cdc.gov/hepatitis/populations/diabetes.htm
iv CDC. https://www.cdc.gov/hepatitis/hbv/bfaq.htm
v CDC. https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm
vi
CDC. https://www.cdc.gov/diabetes/pubs/pdf/hepb_vaccination.pdf
vii
CDC. https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dynavax Technologies (NASDAQ:DVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024